Form 4 Filing for 4D Molecular Therapeutics, Inc.

This filing details stock transactions by Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. On August 13, 2026, Bizily acquired 1635 shares of Common Stock at $4.14 per share and disposed of 1635 shares at $12.00 per share. Concurrently, Bizily exercised stock options for 1635 shares. On August 17, 2026, a similar pattern occurred with the acquisition of 1635 shares at $4.14 and disposal of 1635 shares at $12.20, along with exercising stock options for 1635 shares. These transactions were made pursuant to a 10b5-1 trading plan. The exercise of stock options is subject to vesting conditions.